恩格列净对射血分数降低心衰患者尿酸的影响:EMPEROR-Reduced试验
本研究基于EMPEROR-Reduced试验3676例射血分数降低心衰患者,分析血清尿酸(SUA)与预后的关系及恩格列净的疗效。高尿酸血症患病率53%,最高三分位SUA与复合终点、心血管死亡和全因死亡风险独立相关。恩格列净快速持续降低SUA并减少临床高尿酸血症事件32%,其主要终点获益不依赖基线SUA。
要点
- 心衰患者高尿酸血症常见(53%),最高三分位SUA独立预测更差的复合终点和死亡。
- 恩格列净4周降低SUA约1.12 mg/dL并持续,减少临床高尿酸血症事件32%。
- 恩格列净主要终点获益不依赖基线SUA及4周SUA变化。
核心结论
- 高尿酸血症在心衰中常见,是疾病严重程度和死亡率增加的独立预测因子。
- 恩格列净快速持续降低SUA水平并减少高尿酸血症相关临床事件。
- 恩格列净对主要终点的获益与SUA无关。
研究设计与样本
- EMPEROR-Reduced试验的事后分析,纳入3676例射血分数降低心衰患者(占研究队列98.6%)。
- 分析SUA与复合主要终点(心血管死亡或心衰恶化住院)、其组分及全因死亡的关系。
- 按SUA连续变量、临床高尿酸血症(女性SUA>5.7 mg/dL,男性>7.0 mg/dL)及SUA三分位亚组评估恩格列净疗效。
主要发现
- 高尿酸血症患病率53%,无性别差异。
- 与最低三分位相比,最高三分位(平均SUA 9.38±1.49 mg/dL)与复合终点HR 1.64(95%CI 1.28-2.10)、心血管死亡HR 1.98(95%CI 1.35-2.91)、全因死亡HR 1.8(95%CI 1.29-2.49)相关,均P<0.001。
- 恩格列净治疗4周降低SUA(vs安慰剂:-1.12±0.04 mg/dL,P<0.0001),随访期间持续较低,各预设亚组降幅相似。
- 恩格列净减少临床相关高尿酸血症事件(急性痛风、痛风性关节炎或启动抗痛风治疗)32%[HR 0.68(95%CI 0.52-0.89),P=0.004]。
- 恩格列净对主要终点的获益不依赖基线SUA[HR 0.76(95%CI 0.65-0.88),P<0.001]及4周SUA变化[HR 0.81(95%CI 0.69-0.95),P=0.012];假设生成性交互分析提示高SUA患者死亡获益更明显(交互P=0.005和0.011)。
关键数值与推荐
- 临床高尿酸血症定义:女性SUA>5.7 mg/dL,男性>7.0 mg/dL。
- 最高三分位平均SUA 9.38±1.49 mg/dL。
- 恩格列净4周降低SUA较安慰剂差值为-1.12±0.04 mg/dL(P<0.0001)。
临床怎么用
- 心衰患者应关注SUA水平,高尿酸提示疾病严重程度和死亡风险增加。
- 恩格列净可降低SUA并减少痛风等相关事件,主要获益不依赖基线SUA。
局限性
- 本研究为EMPEROR-Reduced试验的事后分析。
- SUA与疗效的交互分析为假设生成性发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with reduced ejection fraction. Empagliflozin reduces serum uric acid (SUA), but the relevance of this effect in patients with HF is unclear. This study aimed to investigate the effect of empagliflozin on SUA levels and the therapeutic efficacy of empagliflozin in relation to SUA. METHODS: The association between SUA and the composite primary outcome of cardiovascular death or hospitalization for worsening HF, its components, and all-cause mortality was investigated in 3676 patients of the EMPEROR-Reduced trial (98.6% of the study cohort). The treatment effect of empagliflozin was studied in relation to SUA as continuous variable, to clinical hyperuricaemia (SUA >5.7 mg/dL for women, >7.0 mg/dL for men) and in subgroups of patients of tertiles of SUA. RESULTS: Hyperuricaemia was prevalent in 53% of patients with no sex differences. Elevated SUA (highest tertile, mean SUA 9.38 ± 1.49 mg/dL) was associated with advanced severity of HF and with worst outcome [composite outcome, hazard ratio (HR) 1.64 (95% confidence interval, CI 1.28-2.10); cardiovascular mortality, HR 1.98 (95% CI 1.35-2.91); all-cause mortality, HR 1.8 (95% CI 1.29-2.49), all P < 0.001] in multivariate adjusted analyses, as compared with the lowest tertile. SUA was reduced following treatment with empagliflozin at 4 weeks (vs. placebo: -1.12 ± 0.04 mg/dL, P < 0.0001) and remained lower throughout follow-up, with a similar reduction in all prespecified subgroups. Empagliflozin reduced events of clinically relevant hyperuricaemia (acute gout, gouty arthritis or initiation of anti-gout therapy) by 32% [HR 0.68 (95% CI 0.52-0.89), P = 0.004]. The beneficial effect of empagliflozin on the primary endpoint was independent of baseline SUA [HR 0.76 (95% CI 0.65-0.88), P < 0.001) and of the change in SUA at 4 weeks [HR 0.81 (95% CI 0.69-0.95), P = 0.012]. As a hypothesis-generating finding, an interaction between SUA and treatment effect suggested a benefit of empagliflozin on mortality (cardiovascular and all-cause mortality) in patients in elevated SUA (P for interaction = 0.005 and = 0.011, respectively). CONCLUSION: Hyperuricaemia is common in HF and is an independent predictor of advanced disease severity and increased mortality. Empagliflozin induced a rapid and sustained reduction of SUA levels and of clinical events related to hyperuricaemia. The benefit of empagliflozin on the primary outcome was observed independently of SUA.
引用
- Doehner, Anker, Butler, et al. Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. Eur Heart J. 2022. PMID: 35788657. doi:10.1093/eurheartj/ehac320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。